|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:ANP32B-PRKG1 (FusionGDB2 ID:5073) |
Fusion Gene Summary for ANP32B-PRKG1 |
Fusion gene summary |
Fusion gene information | Fusion gene name: ANP32B-PRKG1 | Fusion gene ID: 5073 | Hgene | Tgene | Gene symbol | ANP32B | PRKG1 | Gene ID | 10541 | 5592 |
Gene name | acidic nuclear phosphoprotein 32 family member B | protein kinase cGMP-dependent 1 | |
Synonyms | APRIL|PHAPI2|SSP29 | AAT8|PKG|PKG1|PRKG1B|PRKGR1B|cGK|cGK 1|cGK1|cGKI|cGKI-BETA|cGKI-alpha | |
Cytomap | 9q22.33 | 10q11.23-q21.1 | |
Type of gene | protein-coding | protein-coding | |
Description | acidic leucine-rich nuclear phosphoprotein 32 family member Bacidic (leucine-rich) nuclear phosphoprotein 32 family, member Bacidic protein rich in leucinesputative HLA-DR-associated protein I-2silver-stainable protein SSP29 | cGMP-dependent protein kinase 1protein kinase, cGMP-dependent, regulatory, type I, betaprotein kinase, cGMP-dependent, type I | |
Modification date | 20200313 | 20200322 | |
UniProtAcc | Q92688 | . | |
Ensembl transtripts involved in fusion gene | ENST00000339399, ENST00000473205, | ENST00000401604, ENST00000373985, ENST00000373980, ENST00000373975, | |
Fusion gene scores | * DoF score | 12 X 13 X 4=624 | 14 X 13 X 6=1092 |
# samples | 13 | 14 | |
** MAII score | log2(13/624*10)=-2.26303440583379 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(14/1092*10)=-2.96347412397489 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: ANP32B [Title/Abstract] AND PRKG1 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | ANP32B(100745891)-PRKG1(53814244), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | ANP32B | GO:0006334 | nucleosome assembly | 20538007 |
Hgene | ANP32B | GO:0045596 | negative regulation of cell differentiation | 22705300 |
Tgene | PRKG1 | GO:0006468 | protein phosphorylation | 15905169 |
Tgene | PRKG1 | GO:1904706 | negative regulation of vascular smooth muscle cell proliferation | 25447536 |
Tgene | PRKG1 | GO:1904753 | negative regulation of vascular associated smooth muscle cell migration | 25447536 |
Fusion gene breakpoints across ANP32B (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across PRKG1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | OV | TCGA-13-0720-01A | ANP32B | chr9 | 100745891 | + | PRKG1 | chr10 | 53814244 | + |
Top |
Fusion Gene ORF analysis for ANP32B-PRKG1 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
In-frame | ENST00000339399 | ENST00000401604 | ANP32B | chr9 | 100745891 | + | PRKG1 | chr10 | 53814244 | + |
In-frame | ENST00000339399 | ENST00000373985 | ANP32B | chr9 | 100745891 | + | PRKG1 | chr10 | 53814244 | + |
In-frame | ENST00000339399 | ENST00000373980 | ANP32B | chr9 | 100745891 | + | PRKG1 | chr10 | 53814244 | + |
5CDS-5UTR | ENST00000339399 | ENST00000373975 | ANP32B | chr9 | 100745891 | + | PRKG1 | chr10 | 53814244 | + |
intron-3CDS | ENST00000473205 | ENST00000401604 | ANP32B | chr9 | 100745891 | + | PRKG1 | chr10 | 53814244 | + |
intron-3CDS | ENST00000473205 | ENST00000373985 | ANP32B | chr9 | 100745891 | + | PRKG1 | chr10 | 53814244 | + |
intron-3CDS | ENST00000473205 | ENST00000373980 | ANP32B | chr9 | 100745891 | + | PRKG1 | chr10 | 53814244 | + |
intron-5UTR | ENST00000473205 | ENST00000373975 | ANP32B | chr9 | 100745891 | + | PRKG1 | chr10 | 53814244 | + |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000339399 | ANP32B | chr9 | 100745891 | + | ENST00000401604 | PRKG1 | chr10 | 53814244 | + | 3162 | 249 | 42 | 1547 | 501 |
ENST00000339399 | ANP32B | chr9 | 100745891 | + | ENST00000373985 | PRKG1 | chr10 | 53814244 | + | 5998 | 249 | 42 | 1547 | 501 |
ENST00000339399 | ANP32B | chr9 | 100745891 | + | ENST00000373980 | PRKG1 | chr10 | 53814244 | + | 5998 | 249 | 42 | 1547 | 501 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000339399 | ENST00000401604 | ANP32B | chr9 | 100745891 | + | PRKG1 | chr10 | 53814244 | + | 0.000430713 | 0.99956924 |
ENST00000339399 | ENST00000373985 | ANP32B | chr9 | 100745891 | + | PRKG1 | chr10 | 53814244 | + | 0.000140733 | 0.9998592 |
ENST00000339399 | ENST00000373980 | ANP32B | chr9 | 100745891 | + | PRKG1 | chr10 | 53814244 | + | 0.000140733 | 0.9998592 |
Top |
Fusion Genomic Features for ANP32B-PRKG1 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
ANP32B | chr9 | 100745891 | + | PRKG1 | chr10 | 53814243 | + | 0.88215774 | 0.11784227 |
ANP32B | chr9 | 100745891 | + | PRKG1 | chr10 | 53814243 | + | 0.88215774 | 0.11784227 |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for ANP32B-PRKG1 |
Go to FGviewer for the breakpoints of chr9:100745891-chr10:53814244 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
ANP32B | . |
FUNCTION: Multifunctional protein that is involved in the regulation of many processes including cell proliferation, apoptosis, cell cycle progression or transcription (PubMed:20015864, PubMed:18039846). Regulates the proliferation of neuronal stem cells, differentiation of leukemic cells and progression from G1 to S phase of the cell cycle. As negative regulator of caspase-3-dependent apoptosis, may act as an antagonist of ANP32A in regulating tissue homeostasis (PubMed:20015864). Exhibits histone chaperone properties, able to recruit histones to certain promoters, thus regulating the transcription of specific genes (PubMed:20538007, PubMed:18039846). Plays also an essential role in the nucleocytoplasmic transport of specific mRNAs via the uncommon nuclear mRNA export receptor XPO1/CRM1 (PubMed:17178712). Participates in the regulation of adequate adaptive immune responses by acting on mRNA expression and cell proliferation (By similarity). {ECO:0000250|UniProtKB:Q9EST5, ECO:0000269|PubMed:17178712, ECO:0000269|PubMed:18039846, ECO:0000269|PubMed:20015864, ECO:0000269|PubMed:20538007}.; FUNCTION: (Microbial infection) Plays an essential role in influenza A and B viral genome replication (PubMed:33045004, PubMed:31217244). Plays also a role in foamy virus mRNA export from the nucleus to the cytoplasm (PubMed:21159877). {ECO:0000269|PubMed:21159877, ECO:0000269|PubMed:31217244, ECO:0000269|PubMed:33045004}. | FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000373980 | 4 | 18 | 360_619 | 254.0 | 687.0 | Domain | Protein kinase | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000373980 | 4 | 18 | 620_671 | 254.0 | 687.0 | Domain | AGC-kinase C-terminal | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000401604 | 4 | 18 | 360_619 | 239.0 | 672.0 | Domain | Protein kinase | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000401604 | 4 | 18 | 620_671 | 239.0 | 672.0 | Domain | AGC-kinase C-terminal | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000373980 | 4 | 18 | 291_294 | 254.0 | 687.0 | Nucleotide binding | 3'%2C5'-cGMP 2 | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000373980 | 4 | 18 | 301_302 | 254.0 | 687.0 | Nucleotide binding | 3'%2C5'-cGMP 2 | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000373980 | 4 | 18 | 366_374 | 254.0 | 687.0 | Nucleotide binding | ATP | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000401604 | 4 | 18 | 291_294 | 239.0 | 672.0 | Nucleotide binding | 3'%2C5'-cGMP 2 | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000401604 | 4 | 18 | 301_302 | 239.0 | 672.0 | Nucleotide binding | 3'%2C5'-cGMP 2 | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000401604 | 4 | 18 | 366_374 | 239.0 | 672.0 | Nucleotide binding | ATP |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | ANP32B | chr9:100745891 | chr10:53814244 | ENST00000339399 | + | 1 | 7 | 146_251 | 18.0 | 252.0 | Compositional bias | Note=Asp/Glu-rich (highly acidic) |
Hgene | ANP32B | chr9:100745891 | chr10:53814244 | ENST00000339399 | + | 1 | 7 | 123_161 | 18.0 | 252.0 | Domain | Note=LRRCT |
Hgene | ANP32B | chr9:100745891 | chr10:53814244 | ENST00000339399 | + | 1 | 7 | 239_242 | 18.0 | 252.0 | Motif | Nuclear localization signal |
Hgene | ANP32B | chr9:100745891 | chr10:53814244 | ENST00000339399 | + | 1 | 7 | 16_40 | 18.0 | 252.0 | Repeat | LRR 1 |
Hgene | ANP32B | chr9:100745891 | chr10:53814244 | ENST00000339399 | + | 1 | 7 | 43_64 | 18.0 | 252.0 | Repeat | LRR 2 |
Hgene | ANP32B | chr9:100745891 | chr10:53814244 | ENST00000339399 | + | 1 | 7 | 65_84 | 18.0 | 252.0 | Repeat | LRR 3 |
Hgene | ANP32B | chr9:100745891 | chr10:53814244 | ENST00000339399 | + | 1 | 7 | 89_110 | 18.0 | 252.0 | Repeat | LRR 4 |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000373980 | 4 | 18 | 2_59 | 254.0 | 687.0 | Coiled coil | Ontology_term=ECO:0000269 | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000401604 | 4 | 18 | 2_59 | 239.0 | 672.0 | Coiled coil | Ontology_term=ECO:0000269 | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000373980 | 4 | 18 | 167_170 | 254.0 | 687.0 | Nucleotide binding | 3'%2C5'-cGMP 1 | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000373980 | 4 | 18 | 177_178 | 254.0 | 687.0 | Nucleotide binding | 3'%2C5'-cGMP 1 | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000401604 | 4 | 18 | 167_170 | 239.0 | 672.0 | Nucleotide binding | 3'%2C5'-cGMP 1 | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000401604 | 4 | 18 | 177_178 | 239.0 | 672.0 | Nucleotide binding | 3'%2C5'-cGMP 1 | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000373980 | 4 | 18 | 103_220 | 254.0 | 687.0 | Region | Note=cGMP-binding%2C high affinity | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000373980 | 4 | 18 | 221_341 | 254.0 | 687.0 | Region | Note=cGMP-binding%2C low affinity | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000373980 | 4 | 18 | 2_102 | 254.0 | 687.0 | Region | Note=Required for dimerization | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000373980 | 4 | 18 | 50_75 | 254.0 | 687.0 | Region | Autoinhibitory domain | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000373980 | 4 | 18 | 9_44 | 254.0 | 687.0 | Region | Note=Leucine-zipper | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000401604 | 4 | 18 | 103_220 | 239.0 | 672.0 | Region | Note=cGMP-binding%2C high affinity | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000401604 | 4 | 18 | 221_341 | 239.0 | 672.0 | Region | Note=cGMP-binding%2C low affinity | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000401604 | 4 | 18 | 2_102 | 239.0 | 672.0 | Region | Note=Required for dimerization | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000401604 | 4 | 18 | 50_75 | 239.0 | 672.0 | Region | Autoinhibitory domain | |
Tgene | PRKG1 | chr9:100745891 | chr10:53814244 | ENST00000401604 | 4 | 18 | 9_44 | 239.0 | 672.0 | Region | Note=Leucine-zipper |
Top |
Fusion Gene Sequence for ANP32B-PRKG1 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>In-frame_ENST00000339399_ENST00000401604_TCGA-13-0720-01A_ANP32B_chr9_100745891_+_PRKG1_chr10_53814244_length(transcript)=3162nt_BP=249nt CTCCGCTCCCGTGAGTAACTTGGCTCCGGGGGCTCCGCTCGCCTGCCCGCACGCCGCCCGCCACCCAGGACCGCGCCGCCGGCCTCCGCC GCTAGCAAACCCTTCCGACGGCCCTCGCTGCGCAAGCCGGGACGCCTCTCCCCCCTCCGCCCCCGCCGCGGAAAGTTAAGTTTGAAGAGG GGGGAAGAGGGGAACATGGACATGAAGAGGAGGATCCACCTGGAGCTGAGGAACCGGACCCCGGCAGCTACCCACTATGAAAATGGAGAA TATATTATCAGGCAAGGTGCAAGAGGGGACACCTTCTTTATCATCAGCAAAGGAACGGTAAATGTCACTCGTGAAGACTCACCGAGTGAA GACCCAGTCTTTCTTAGAACTTTAGGAAAAGGAGACTGGTTTGGAGAGAAAGCCTTGCAGGGGGAAGATGTGAGAACAGCAAACGTAATT GCTGCAGAAGCTGTAACCTGCCTTGTGATTGACAGAGACTCTTTTAAACATTTGATTGGAGGGCTGGATGATGTTTCTAATAAAGCATAT GAAGATGCAGAAGCTAAAGCAAAATATGAAGCTGAAGCGGCTTTCTTCGCCAACCTGAAGCTGTCTGATTTCAACATCATTGATACCCTT GGAGTTGGAGGTTTCGGACGAGTAGAACTGGTCCAGTTGAAAAGTGAAGAATCCAAAACGTTTGCAATGAAGATTCTCAAGAAACGTCAC ATTGTGGACACAAGACAGCAGGAGCACATCCGCTCAGAGAAGCAGATCATGCAGGGGGCTCATTCCGATTTCATAGTGAGACTGTACAGA ACATTTAAGGACAGCAAATATTTGTATATGTTGATGGAAGCTTGTCTAGGTGGAGAGCTCTGGACCATTCTCAGGGATAGAGGTTCGTTT GAAGATTCTACAACCAGATTTTACACAGCATGTGTGGTAGAAGCTTTTGCCTATCTGCATTCCAAAGGAATCATTTACAGGGACCTCAAG CCAGAAAATCTCATCCTAGATCACCGAGGTTATGCCAAACTGGTTGATTTTGGCTTTGCAAAGAAAATAGGATTTGGAAAGAAAACATGG ACTTTTTGTGGGACTCCAGAGTATGTAGCCCCAGAGATCATCCTGAACAAAGGCCATGACATTTCAGCCGACTACTGGTCACTGGGAATC CTAATGTATGAACTCCTGACTGGCAGCCCACCTTTCTCAGGCCCAGATCCTATGAAAACCTATAACATCATATTGAGGGGGATTGACATG ATAGAATTTCCAAAGAAGATTGCCAAAAATGCTGCTAATTTAATTAAAAAACTATGCAGGGACAATCCATCAGAAAGATTAGGGAATTTG AAAAATGGAGTAAAAGACATTCAAAAGCACAAATGGTTTGAGGGCTTTAACTGGGAAGGCTTAAGAAAAGGTACCTTGACACCTCCTATA ATACCAAGTGTTGCATCACCCACAGACACAAGTAATTTTGACAGTTTCCCTGAGGACAACGATGAACCACCACCTGATGACAACTCAGGA TGGGATATAGACTTCTAATGTATTTCTCTTACCTGCTTCTGCCTTGCTGAAGACAGCTTTTTCTGAGACACAGCTGCCAGCAAACCTGAG GGAAAGAGAGAAGATTAGTGCTCGGGGTCACCATGATGCCTTTGATCGATGCTGCTCCAGTAACTACAGTGGCATTAGGACTTACCGCTT AGATGACAATAGTGCTCTTTACATGTTTTCTGTTTGAACCTAAAATAGCAGTTGACATGGTGGTCCTGAAGCAAAGCCTTTCACCAGTAA AAGATGTTTTCTATTGTTGCAATGACCTTGCTTTGCTCTGATTATAATTTGAAAGACTGTAGGAAACACTTCAATGTAGTATAAGAGTCT GTACCTTGCTGGAATATTCAAGAAGATGAAAGAATAATATATTGGGTACAATAGATTACTATGGTACAGAAACTGGGCTATTCCCTTTCT TCAAGTGAAGGCTGTGGGATCTATTACTGCAGGCCGGTGTATATACCATACAAAAGAGGACCACACATCTGTTGGTCACAGAGTTCATGT CACACCAGTGCTAGAAGTTTCATGATTTTATTTCCCAGCAGTGCTGATGACAAGACTGAATGTTACCTTTTCTTTCTGACAGATTTTAAA AATTGATATGATAAAAGCACAACTGCTATAGATTCTGCTGAGACCTCTCATAGTAGGTATATATGAGTTTTCACAGAAGACTGAAAAATA ATGCATGATATTTGTTTGTTTTTTTTGATAAATTGGCATGACAGAGTGGGGAAAAAAAGCAATTCACAAAACCATTTCATATTTTTTAAA ATATTGTGCTTAAAGATGGTCCTGGAAGTAAATGACTAGCAGCCAATTGGTTTTACTTAACATACCCTCAAACTGAGGCTTAAAGTATTC CCTTTTATAAAAATAAATGCTTGGGGTAGGGTGGAGTGGGGAGGGATTAAAACCCATCCAAAAAATAAATAAAAACTATATAGGTGCTAT GTATATCTTTCATCTGTAAATGTCAGTGTCTGAACAGACAACACAAATTCAAATCATTATACGTGTAGCCAGAAACTCAAGCATTTTCAC TAAAGTTATTAAACCAAACTCCTGTCCAATTTCACTTATACAACATAGTCAGTCTAGAGTTGAGAGACAAAGGTAATTATAAACCTATTT GAACTAGCTTCTTGTCTTAGGCCTGAACCAAAAAACAACAAACAAACAAAAAACAAGAATGAAAAACAGAAATAAAAGAAGTAGAAAAGA CAAAGAAAGAAAGCCCAAAGTCAAAGTTGTTAATATTTACAGGTTTACCAGATCTGGAACATTACTTATTTGAGGTCAGAGAACAAAACA AGAACCTGGCCAGGTGTTGATTACCTTTTAGTGAATAAGCTGAGTCCATATACTTGTCTAACTAAGAAAGCAGTACAGAGGAAAACAGGA ACCTGATTTTTTTAAAATAAATTTTAAATAAAATAGAATTACTACAATTCTGCAATTTCATACTACCTAAAAAAGACTAGATTTGAAAAT GTCAAGCTGATTTACTTTATTCACATGGAGAAAAGAATCCACAAATTAAACTGAGTCCTTCACTGGCATGCCAGTTGACTATTATTAGCT >In-frame_ENST00000339399_ENST00000401604_TCGA-13-0720-01A_ANP32B_chr9_100745891_+_PRKG1_chr10_53814244_length(amino acids)=501AA_start in transcript=42_stop in transcript=1547 MPARRPPPRTAPPASAASKPFRRPSLRKPGRLSPLRPRRGKLSLKRGEEGNMDMKRRIHLELRNRTPAATHYENGEYIIRQGARGDTFFI ISKGTVNVTREDSPSEDPVFLRTLGKGDWFGEKALQGEDVRTANVIAAEAVTCLVIDRDSFKHLIGGLDDVSNKAYEDAEAKAKYEAEAA FFANLKLSDFNIIDTLGVGGFGRVELVQLKSEESKTFAMKILKKRHIVDTRQQEHIRSEKQIMQGAHSDFIVRLYRTFKDSKYLYMLMEA CLGGELWTILRDRGSFEDSTTRFYTACVVEAFAYLHSKGIIYRDLKPENLILDHRGYAKLVDFGFAKKIGFGKKTWTFCGTPEYVAPEII LNKGHDISADYWSLGILMYELLTGSPPFSGPDPMKTYNIILRGIDMIEFPKKIAKNAANLIKKLCRDNPSERLGNLKNGVKDIQKHKWFE -------------------------------------------------------------- >In-frame_ENST00000339399_ENST00000373985_TCGA-13-0720-01A_ANP32B_chr9_100745891_+_PRKG1_chr10_53814244_length(transcript)=5998nt_BP=249nt CTCCGCTCCCGTGAGTAACTTGGCTCCGGGGGCTCCGCTCGCCTGCCCGCACGCCGCCCGCCACCCAGGACCGCGCCGCCGGCCTCCGCC GCTAGCAAACCCTTCCGACGGCCCTCGCTGCGCAAGCCGGGACGCCTCTCCCCCCTCCGCCCCCGCCGCGGAAAGTTAAGTTTGAAGAGG GGGGAAGAGGGGAACATGGACATGAAGAGGAGGATCCACCTGGAGCTGAGGAACCGGACCCCGGCAGCTACCCACTATGAAAATGGAGAA TATATTATCAGGCAAGGTGCAAGAGGGGACACCTTCTTTATCATCAGCAAAGGAACGGTAAATGTCACTCGTGAAGACTCACCGAGTGAA GACCCAGTCTTTCTTAGAACTTTAGGAAAAGGAGACTGGTTTGGAGAGAAAGCCTTGCAGGGGGAAGATGTGAGAACAGCAAACGTAATT GCTGCAGAAGCTGTAACCTGCCTTGTGATTGACAGAGACTCTTTTAAACATTTGATTGGAGGGCTGGATGATGTTTCTAATAAAGCATAT GAAGATGCAGAAGCTAAAGCAAAATATGAAGCTGAAGCGGCTTTCTTCGCCAACCTGAAGCTGTCTGATTTCAACATCATTGATACCCTT GGAGTTGGAGGTTTCGGACGAGTAGAACTGGTCCAGTTGAAAAGTGAAGAATCCAAAACGTTTGCAATGAAGATTCTCAAGAAACGTCAC ATTGTGGACACAAGACAGCAGGAGCACATCCGCTCAGAGAAGCAGATCATGCAGGGGGCTCATTCCGATTTCATAGTGAGACTGTACAGA ACATTTAAGGACAGCAAATATTTGTATATGTTGATGGAAGCTTGTCTAGGTGGAGAGCTCTGGACCATTCTCAGGGATAGAGGTTCGTTT GAAGATTCTACAACCAGATTTTACACAGCATGTGTGGTAGAAGCTTTTGCCTATCTGCATTCCAAAGGAATCATTTACAGGGACCTCAAG CCAGAAAATCTCATCCTAGATCACCGAGGTTATGCCAAACTGGTTGATTTTGGCTTTGCAAAGAAAATAGGATTTGGAAAGAAAACATGG ACTTTTTGTGGGACTCCAGAGTATGTAGCCCCAGAGATCATCCTGAACAAAGGCCATGACATTTCAGCCGACTACTGGTCACTGGGAATC CTAATGTATGAACTCCTGACTGGCAGCCCACCTTTCTCAGGCCCAGATCCTATGAAAACCTATAACATCATATTGAGGGGGATTGACATG ATAGAATTTCCAAAGAAGATTGCCAAAAATGCTGCTAATTTAATTAAAAAACTATGCAGGGACAATCCATCAGAAAGATTAGGGAATTTG AAAAATGGAGTAAAAGACATTCAAAAGCACAAATGGTTTGAGGGCTTTAACTGGGAAGGCTTAAGAAAAGGTACCTTGACACCTCCTATA ATACCAAGTGTTGCATCACCCACAGACACAAGTAATTTTGACAGTTTCCCTGAGGACAACGATGAACCACCACCTGATGACAACTCAGGA TGGGATATAGACTTCTAATGTATTTCTCTTACCTGCTTCTGCCTTGCTGAAGACAGCTTTTTCTGAGACACAGCTGCCAGCAAACCTGAG GGAAAGAGAGAAGATTAGTGCTCGGGGTCACCATGATGCCTTTGATCGATGCTGCTCCAGTAACTACAGTGGCATTAGGACTTACCGCTT AGATGACAATAGTGCTCTTTACATGTTTTCTGTTTGAACCTAAAATAGCAGTTGACATGGTGGTCCTGAAGCAAAGCCTTTCACCAGTAA AAGATGTTTTCTATTGTTGCAATGACCTTGCTTTGCTCTGATTATAATTTGAAAGACTGTAGGAAACACTTCAATGTAGTATAAGAGTCT GTACCTTGCTGGAATATTCAAGAAGATGAAAGAATAATATATTGGGTACAATAGATTACTATGGTACAGAAACTGGGCTATTCCCTTTCT TCAAGTGAAGGCTGTGGGATCTATTACTGCAGGCCGGTGTATATACCATACAAAAGAGGACCACACATCTGTTGGTCACAGAGTTCATGT CACACCAGTGCTAGAAGTTTCATGATTTTATTTCCCAGCAGTGCTGATGACAAGACTGAATGTTACCTTTTCTTTCTGACAGATTTTAAA AATTGATATGATAAAAGCACAACTGCTATAGATTCTGCTGAGACCTCTCATAGTAGGTATATATGAGTTTTCACAGAAGACTGAAAAATA ATGCATGATATTTGTTTGTTTTTTTTGATAAATTGGCATGACAGAGTGGGGAAAAAAAGCAATTCACAAAACCATTTCATATTTTTTAAA ATATTGTGCTTAAAGATGGTCCTGGAAGTAAATGACTAGCAGCCAATTGGTTTTACTTAACATACCCTCAAACTGAGGCTTAAAGTATTC CCTTTTATAAAAATAAATGCTTGGGGTAGGGTGGAGTGGGGAGGGATTAAAACCCATCCAAAAAATAAATAAAAACTATATAGGTGCTAT GTATATCTTTCATCTGTAAATGTCAGTGTCTGAACAGACAACACAAATTCAAATCATTATACGTGTAGCCAGAAACTCAAGCATTTTCAC TAAAGTTATTAAACCAAACTCCTGTCCAATTTCACTTATACAACATAGTCAGTCTAGAGTTGAGAGACAAAGGTAATTATAAACCTATTT GAACTAGCTTCTTGTCTTAGGCCTGAACCAAAAAACAACAAACAAACAAAAAACAAGAATGAAAAACAGAAATAAAAGAAGTAGAAAAGA CAAAGAAAGAAAGCCCAAAGTCAAAGTTGTTAATATTTACAGGTTTACCAGATCTGGAACATTACTTATTTGAGGTCAGAGAACAAAACA AGAACCTGGCCAGGTGTTGATTACCTTTTAGTGAATAAGCTGAGTCCATATACTTGTCTAACTAAGAAAGCAGTACAGAGGAAAACAGGA ACCTGATTTTTTTAAAATAAATTTTAAATAAAATAGAATTACTACAATTCTGCAATTTCATACTACCTAAAAAAGACTAGATTTGAAAAT GTCAAGCTGATTTACTTTATTCACATGGAGAAAAGAATCCACAAATTAAACTGAGTCCTTCACTGGCATGCCAGTTGACTATTATTAGCT GTCATAAGTAACTCAGCCATTTGGAAGCATTTCCTGGACAAAATTACATTATACCTGTGAAGAAAAATATAGAAGCTTTCAAGCTGTCAT TCTGTTTTGGCCCTGTGTGAATTTGGTATATTAAATTGACGCTTGCTTTTTTTTTCAGTAGAGTTTTCTTTTTAATCAATCAAACGCCTA CATTTCTGGAAGAAAAAGTCCAATTAGATCATTACACCTTAACTAAGAAGGCAAATCTTATAAATTTTGCTTGAATTGTTCTTACTCAAA ACTACCTTAGAATATGGTATCTTATGAAAATATAATATTCTTAAAATTTTGGAGGATAAAATGAAAAGGGTATAAACTTCAATTAGAACT TTAATCCTAAAATATTGTTATTCTTGTATTTTTGGAGTTTTCCGTCCCTTACAATTTCTCCAAATTGGTCTATTCCCCAAGATATCCACT GTTTTCTACAGATTTTAGAATATAAAATTAAACATATCAACCTAAAATCTAGCTATGAATGTTATTTCAAGAGTTTTATATTTTTAATTG GCTTTTTAAAAATATGTAATTCCAATATTATAGTGAATGTTCAGTAACTTTTGTTGAAAGATAATGTGGTTTAGGCTTGCTAAAGAAAGG CTTGCTAGAATACTAAATTTACCTTGTTATTTGGAAAGAGAATCTGCTCCTATAACGTTTTAAAAATCCCCAAAGTCCCAGAGATTAGCA CTTGCTATGGATTTTGGAACTATGGTTCAAGTCTAAGACAACCAATATGAATAAGTTCAATGGAGAAGGAAGAAGTAGCATTCAGCACAA GAAACTGTAGATTGTTTCTCCCACTTGTTACTGCATCTTTGTTCATTTCACCCATAGCATTGCATTTGATGTCTGAAGTAATTACCACAA AATAAAGGTAAACTACATCTTCCAAGATGTACCAACAGAAAACATTCGTCTAATTTTGTCAACATTGAATTTTTAGGATTTAAATCTTGT CTTAATGAAGACTCTAGGGCTAAAATTCATGGTCAGTTCCATAAAATGCATCTCACTTTATTTCTGAATTTTTCACAACCCCTCTATTTT CTTACATTAAAGAACATCTGGATAAGTTAGAATAGTGCCAACTTGTTTGATTTGTTATATGATTTTCTTGTTAATGTGTTGAGTATGGGA AATAAGGGCTTTCTGTGTGTCTTGACTCACAGGAAAACTGAAACTGCCAAGGGAAGCAACATTAAAACAACTGGGATAGATTGAATACAT TTGAAAAAATAATTTCTGGAAAAACGCTATACATGCTTTTTATGTTTATATCTTCTTTCTTATTAAGACATGAATCAGATCCATGTGGCA TTCAAAACAAATTTATTTTGGTTATATTCTTTACAAGTCATAATTTTTACCTAAAATTGTGGAATATGCATGTGAATTACACATGTGTAG TAATAAACTCAACTATTGAATTTTTCCTGTTTCATTTCTAAATGACTGAACTGATGGTAAACAAATTTAATGAAGTCAGCTACCATGTTG AAAATAAGGATATTAGAACTGATTTCATACAATAGAGGTGATCTGTGCATTATCCATAACAACGTTTTCTTTCACTATAGGACCACAGAC AAATATTTATGTAAATAGGTATTTTTGTGTGATATTTTGTGGTACATATAACTTTTTTTAGTGTTTCACAGCATTATTATTTCATTTTAT TTGTATTGAATAATGTTTTTAGGTCCAAGTAGACTTGAATTAATGTCATAATTGTCAGTATTATTGAAAATTATGTCAACTGTACTGTTA TTCATCTGTCCCATAGTTTAGAACATGACCTGGCTATCTGGCATTGTTGCAAGTGCCTTAAATTCATGGCATCCTATTAAAAAAACAAAT TTGGTGTTATGCTGCATGACAAAGACAAACACACCTCAAAATGTTGTCCTTTCTTAGCTTGCTGCGTTTTACAGTTCTTTCTGCTAACAA TTTATAAGCCTTTATTATATAATATTGATGAATTACAGAAATGATGAAGTTGTTCTCTTATTTCTGTTAAATGTACCAGAGCTGTGTATC TGTTAATGAGATACAGCGTCATTTCTGTGAAATGTATAAATGTATGTGCAGGTCAAATTAATATATGACATTCTATCAGTCTGTATACAG GTATTCCTGTTTTGCTAAGCTGTGCAGATTCTGTAAAAATAAATTAGTGCAGTCAAGTTCTAACATATCTCATTTTATAGACTCCATTGA CAATGGTCCAACCGAAAAGAAAAATTGGAAATGACTGCTAACCAGACCTCGTTATGAAACCAATGATGAAAAAGTCACTTGGTGCACCTC TCAACAAAACAGGATGCTTTTTCCGAGTTCTTGTATATGCAAATCATTTACGAGGCAAGTTTTCAACAGACCTAGAAAGCAAAACATTGA AAGTGTGTTGTTAGCCCTCCTCTCTGCCCCTGAATCAACAGACAGAGCTCTGGGACCTTGGCAATGACTCAGAGGTTGGGGCTTTCTGAG TAAAGGGACATTTCTTTAAGCATCATCTATCAAATTTATTTCAATGTATGATGTTTTTACAACTGGTCAGTTCTTTTGTATTCTTACAGC TATGGTTATTTGATTGTCCTCTTACAATTTGTTCTACATGAAAGAGTTCTTTGTTAGTCAGAATGCAACAAACTGTCATCAAATGGTCAT TGACCACTTGCACTCTTTTGATGTAGATTAAAAACTTTTTCATAAATTTACCTGCTTTGATTTGCTCTGTATTTTTCCTGCAGCTGTAAT >In-frame_ENST00000339399_ENST00000373985_TCGA-13-0720-01A_ANP32B_chr9_100745891_+_PRKG1_chr10_53814244_length(amino acids)=501AA_start in transcript=42_stop in transcript=1547 MPARRPPPRTAPPASAASKPFRRPSLRKPGRLSPLRPRRGKLSLKRGEEGNMDMKRRIHLELRNRTPAATHYENGEYIIRQGARGDTFFI ISKGTVNVTREDSPSEDPVFLRTLGKGDWFGEKALQGEDVRTANVIAAEAVTCLVIDRDSFKHLIGGLDDVSNKAYEDAEAKAKYEAEAA FFANLKLSDFNIIDTLGVGGFGRVELVQLKSEESKTFAMKILKKRHIVDTRQQEHIRSEKQIMQGAHSDFIVRLYRTFKDSKYLYMLMEA CLGGELWTILRDRGSFEDSTTRFYTACVVEAFAYLHSKGIIYRDLKPENLILDHRGYAKLVDFGFAKKIGFGKKTWTFCGTPEYVAPEII LNKGHDISADYWSLGILMYELLTGSPPFSGPDPMKTYNIILRGIDMIEFPKKIAKNAANLIKKLCRDNPSERLGNLKNGVKDIQKHKWFE -------------------------------------------------------------- >In-frame_ENST00000339399_ENST00000373980_TCGA-13-0720-01A_ANP32B_chr9_100745891_+_PRKG1_chr10_53814244_length(transcript)=5998nt_BP=249nt CTCCGCTCCCGTGAGTAACTTGGCTCCGGGGGCTCCGCTCGCCTGCCCGCACGCCGCCCGCCACCCAGGACCGCGCCGCCGGCCTCCGCC GCTAGCAAACCCTTCCGACGGCCCTCGCTGCGCAAGCCGGGACGCCTCTCCCCCCTCCGCCCCCGCCGCGGAAAGTTAAGTTTGAAGAGG GGGGAAGAGGGGAACATGGACATGAAGAGGAGGATCCACCTGGAGCTGAGGAACCGGACCCCGGCAGCTACCCACTATGAAAATGGAGAA TATATTATCAGGCAAGGTGCAAGAGGGGACACCTTCTTTATCATCAGCAAAGGAACGGTAAATGTCACTCGTGAAGACTCACCGAGTGAA GACCCAGTCTTTCTTAGAACTTTAGGAAAAGGAGACTGGTTTGGAGAGAAAGCCTTGCAGGGGGAAGATGTGAGAACAGCAAACGTAATT GCTGCAGAAGCTGTAACCTGCCTTGTGATTGACAGAGACTCTTTTAAACATTTGATTGGAGGGCTGGATGATGTTTCTAATAAAGCATAT GAAGATGCAGAAGCTAAAGCAAAATATGAAGCTGAAGCGGCTTTCTTCGCCAACCTGAAGCTGTCTGATTTCAACATCATTGATACCCTT GGAGTTGGAGGTTTCGGACGAGTAGAACTGGTCCAGTTGAAAAGTGAAGAATCCAAAACGTTTGCAATGAAGATTCTCAAGAAACGTCAC ATTGTGGACACAAGACAGCAGGAGCACATCCGCTCAGAGAAGCAGATCATGCAGGGGGCTCATTCCGATTTCATAGTGAGACTGTACAGA ACATTTAAGGACAGCAAATATTTGTATATGTTGATGGAAGCTTGTCTAGGTGGAGAGCTCTGGACCATTCTCAGGGATAGAGGTTCGTTT GAAGATTCTACAACCAGATTTTACACAGCATGTGTGGTAGAAGCTTTTGCCTATCTGCATTCCAAAGGAATCATTTACAGGGACCTCAAG CCAGAAAATCTCATCCTAGATCACCGAGGTTATGCCAAACTGGTTGATTTTGGCTTTGCAAAGAAAATAGGATTTGGAAAGAAAACATGG ACTTTTTGTGGGACTCCAGAGTATGTAGCCCCAGAGATCATCCTGAACAAAGGCCATGACATTTCAGCCGACTACTGGTCACTGGGAATC CTAATGTATGAACTCCTGACTGGCAGCCCACCTTTCTCAGGCCCAGATCCTATGAAAACCTATAACATCATATTGAGGGGGATTGACATG ATAGAATTTCCAAAGAAGATTGCCAAAAATGCTGCTAATTTAATTAAAAAACTATGCAGGGACAATCCATCAGAAAGATTAGGGAATTTG AAAAATGGAGTAAAAGACATTCAAAAGCACAAATGGTTTGAGGGCTTTAACTGGGAAGGCTTAAGAAAAGGTACCTTGACACCTCCTATA ATACCAAGTGTTGCATCACCCACAGACACAAGTAATTTTGACAGTTTCCCTGAGGACAACGATGAACCACCACCTGATGACAACTCAGGA TGGGATATAGACTTCTAATGTATTTCTCTTACCTGCTTCTGCCTTGCTGAAGACAGCTTTTTCTGAGACACAGCTGCCAGCAAACCTGAG GGAAAGAGAGAAGATTAGTGCTCGGGGTCACCATGATGCCTTTGATCGATGCTGCTCCAGTAACTACAGTGGCATTAGGACTTACCGCTT AGATGACAATAGTGCTCTTTACATGTTTTCTGTTTGAACCTAAAATAGCAGTTGACATGGTGGTCCTGAAGCAAAGCCTTTCACCAGTAA AAGATGTTTTCTATTGTTGCAATGACCTTGCTTTGCTCTGATTATAATTTGAAAGACTGTAGGAAACACTTCAATGTAGTATAAGAGTCT GTACCTTGCTGGAATATTCAAGAAGATGAAAGAATAATATATTGGGTACAATAGATTACTATGGTACAGAAACTGGGCTATTCCCTTTCT TCAAGTGAAGGCTGTGGGATCTATTACTGCAGGCCGGTGTATATACCATACAAAAGAGGACCACACATCTGTTGGTCACAGAGTTCATGT CACACCAGTGCTAGAAGTTTCATGATTTTATTTCCCAGCAGTGCTGATGACAAGACTGAATGTTACCTTTTCTTTCTGACAGATTTTAAA AATTGATATGATAAAAGCACAACTGCTATAGATTCTGCTGAGACCTCTCATAGTAGGTATATATGAGTTTTCACAGAAGACTGAAAAATA ATGCATGATATTTGTTTGTTTTTTTTGATAAATTGGCATGACAGAGTGGGGAAAAAAAGCAATTCACAAAACCATTTCATATTTTTTAAA ATATTGTGCTTAAAGATGGTCCTGGAAGTAAATGACTAGCAGCCAATTGGTTTTACTTAACATACCCTCAAACTGAGGCTTAAAGTATTC CCTTTTATAAAAATAAATGCTTGGGGTAGGGTGGAGTGGGGAGGGATTAAAACCCATCCAAAAAATAAATAAAAACTATATAGGTGCTAT GTATATCTTTCATCTGTAAATGTCAGTGTCTGAACAGACAACACAAATTCAAATCATTATACGTGTAGCCAGAAACTCAAGCATTTTCAC TAAAGTTATTAAACCAAACTCCTGTCCAATTTCACTTATACAACATAGTCAGTCTAGAGTTGAGAGACAAAGGTAATTATAAACCTATTT GAACTAGCTTCTTGTCTTAGGCCTGAACCAAAAAACAACAAACAAACAAAAAACAAGAATGAAAAACAGAAATAAAAGAAGTAGAAAAGA CAAAGAAAGAAAGCCCAAAGTCAAAGTTGTTAATATTTACAGGTTTACCAGATCTGGAACATTACTTATTTGAGGTCAGAGAACAAAACA AGAACCTGGCCAGGTGTTGATTACCTTTTAGTGAATAAGCTGAGTCCATATACTTGTCTAACTAAGAAAGCAGTACAGAGGAAAACAGGA ACCTGATTTTTTTAAAATAAATTTTAAATAAAATAGAATTACTACAATTCTGCAATTTCATACTACCTAAAAAAGACTAGATTTGAAAAT GTCAAGCTGATTTACTTTATTCACATGGAGAAAAGAATCCACAAATTAAACTGAGTCCTTCACTGGCATGCCAGTTGACTATTATTAGCT GTCATAAGTAACTCAGCCATTTGGAAGCATTTCCTGGACAAAATTACATTATACCTGTGAAGAAAAATATAGAAGCTTTCAAGCTGTCAT TCTGTTTTGGCCCTGTGTGAATTTGGTATATTAAATTGACGCTTGCTTTTTTTTTCAGTAGAGTTTTCTTTTTAATCAATCAAACGCCTA CATTTCTGGAAGAAAAAGTCCAATTAGATCATTACACCTTAACTAAGAAGGCAAATCTTATAAATTTTGCTTGAATTGTTCTTACTCAAA ACTACCTTAGAATATGGTATCTTATGAAAATATAATATTCTTAAAATTTTGGAGGATAAAATGAAAAGGGTATAAACTTCAATTAGAACT TTAATCCTAAAATATTGTTATTCTTGTATTTTTGGAGTTTTCCGTCCCTTACAATTTCTCCAAATTGGTCTATTCCCCAAGATATCCACT GTTTTCTACAGATTTTAGAATATAAAATTAAACATATCAACCTAAAATCTAGCTATGAATGTTATTTCAAGAGTTTTATATTTTTAATTG GCTTTTTAAAAATATGTAATTCCAATATTATAGTGAATGTTCAGTAACTTTTGTTGAAAGATAATGTGGTTTAGGCTTGCTAAAGAAAGG CTTGCTAGAATACTAAATTTACCTTGTTATTTGGAAAGAGAATCTGCTCCTATAACGTTTTAAAAATCCCCAAAGTCCCAGAGATTAGCA CTTGCTATGGATTTTGGAACTATGGTTCAAGTCTAAGACAACCAATATGAATAAGTTCAATGGAGAAGGAAGAAGTAGCATTCAGCACAA GAAACTGTAGATTGTTTCTCCCACTTGTTACTGCATCTTTGTTCATTTCACCCATAGCATTGCATTTGATGTCTGAAGTAATTACCACAA AATAAAGGTAAACTACATCTTCCAAGATGTACCAACAGAAAACATTCGTCTAATTTTGTCAACATTGAATTTTTAGGATTTAAATCTTGT CTTAATGAAGACTCTAGGGCTAAAATTCATGGTCAGTTCCATAAAATGCATCTCACTTTATTTCTGAATTTTTCACAACCCCTCTATTTT CTTACATTAAAGAACATCTGGATAAGTTAGAATAGTGCCAACTTGTTTGATTTGTTATATGATTTTCTTGTTAATGTGTTGAGTATGGGA AATAAGGGCTTTCTGTGTGTCTTGACTCACAGGAAAACTGAAACTGCCAAGGGAAGCAACATTAAAACAACTGGGATAGATTGAATACAT TTGAAAAAATAATTTCTGGAAAAACGCTATACATGCTTTTTATGTTTATATCTTCTTTCTTATTAAGACATGAATCAGATCCATGTGGCA TTCAAAACAAATTTATTTTGGTTATATTCTTTACAAGTCATAATTTTTACCTAAAATTGTGGAATATGCATGTGAATTACACATGTGTAG TAATAAACTCAACTATTGAATTTTTCCTGTTTCATTTCTAAATGACTGAACTGATGGTAAACAAATTTAATGAAGTCAGCTACCATGTTG AAAATAAGGATATTAGAACTGATTTCATACAATAGAGGTGATCTGTGCATTATCCATAACAACGTTTTCTTTCACTATAGGACCACAGAC AAATATTTATGTAAATAGGTATTTTTGTGTGATATTTTGTGGTACATATAACTTTTTTTAGTGTTTCACAGCATTATTATTTCATTTTAT TTGTATTGAATAATGTTTTTAGGTCCAAGTAGACTTGAATTAATGTCATAATTGTCAGTATTATTGAAAATTATGTCAACTGTACTGTTA TTCATCTGTCCCATAGTTTAGAACATGACCTGGCTATCTGGCATTGTTGCAAGTGCCTTAAATTCATGGCATCCTATTAAAAAAACAAAT TTGGTGTTATGCTGCATGACAAAGACAAACACACCTCAAAATGTTGTCCTTTCTTAGCTTGCTGCGTTTTACAGTTCTTTCTGCTAACAA TTTATAAGCCTTTATTATATAATATTGATGAATTACAGAAATGATGAAGTTGTTCTCTTATTTCTGTTAAATGTACCAGAGCTGTGTATC TGTTAATGAGATACAGCGTCATTTCTGTGAAATGTATAAATGTATGTGCAGGTCAAATTAATATATGACATTCTATCAGTCTGTATACAG GTATTCCTGTTTTGCTAAGCTGTGCAGATTCTGTAAAAATAAATTAGTGCAGTCAAGTTCTAACATATCTCATTTTATAGACTCCATTGA CAATGGTCCAACCGAAAAGAAAAATTGGAAATGACTGCTAACCAGACCTCGTTATGAAACCAATGATGAAAAAGTCACTTGGTGCACCTC TCAACAAAACAGGATGCTTTTTCCGAGTTCTTGTATATGCAAATCATTTACGAGGCAAGTTTTCAACAGACCTAGAAAGCAAAACATTGA AAGTGTGTTGTTAGCCCTCCTCTCTGCCCCTGAATCAACAGACAGAGCTCTGGGACCTTGGCAATGACTCAGAGGTTGGGGCTTTCTGAG TAAAGGGACATTTCTTTAAGCATCATCTATCAAATTTATTTCAATGTATGATGTTTTTACAACTGGTCAGTTCTTTTGTATTCTTACAGC TATGGTTATTTGATTGTCCTCTTACAATTTGTTCTACATGAAAGAGTTCTTTGTTAGTCAGAATGCAACAAACTGTCATCAAATGGTCAT TGACCACTTGCACTCTTTTGATGTAGATTAAAAACTTTTTCATAAATTTACCTGCTTTGATTTGCTCTGTATTTTTCCTGCAGCTGTAAT >In-frame_ENST00000339399_ENST00000373980_TCGA-13-0720-01A_ANP32B_chr9_100745891_+_PRKG1_chr10_53814244_length(amino acids)=501AA_start in transcript=42_stop in transcript=1547 MPARRPPPRTAPPASAASKPFRRPSLRKPGRLSPLRPRRGKLSLKRGEEGNMDMKRRIHLELRNRTPAATHYENGEYIIRQGARGDTFFI ISKGTVNVTREDSPSEDPVFLRTLGKGDWFGEKALQGEDVRTANVIAAEAVTCLVIDRDSFKHLIGGLDDVSNKAYEDAEAKAKYEAEAA FFANLKLSDFNIIDTLGVGGFGRVELVQLKSEESKTFAMKILKKRHIVDTRQQEHIRSEKQIMQGAHSDFIVRLYRTFKDSKYLYMLMEA CLGGELWTILRDRGSFEDSTTRFYTACVVEAFAYLHSKGIIYRDLKPENLILDHRGYAKLVDFGFAKKIGFGKKTWTFCGTPEYVAPEII LNKGHDISADYWSLGILMYELLTGSPPFSGPDPMKTYNIILRGIDMIEFPKKIAKNAANLIKKLCRDNPSERLGNLKNGVKDIQKHKWFE -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for ANP32B-PRKG1 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ANP32B-PRKG1 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for ANP32B-PRKG1 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | PRKG1 | C4707243 | Familial thoracic aortic aneurysm and aortic dissection | 3 | CLINGEN;GENOMICS_ENGLAND;ORPHANET |
Tgene | PRKG1 | C3809513 | AORTIC ANEURYSM, FAMILIAL THORACIC 8 | 2 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Tgene | PRKG1 | C0020542 | Pulmonary Hypertension | 1 | CTD_human |
Tgene | PRKG1 | C0027796 | Neuralgia | 1 | CTD_human |
Tgene | PRKG1 | C0032927 | Precancerous Conditions | 1 | CTD_human |
Tgene | PRKG1 | C0036920 | Sezary Syndrome | 1 | CTD_human |
Tgene | PRKG1 | C0038870 | Neuralgia, Supraorbital | 1 | CTD_human |
Tgene | PRKG1 | C0042656 | Neuralgia, Vidian | 1 | CTD_human |
Tgene | PRKG1 | C0234247 | Neuralgia, Atypical | 1 | CTD_human |
Tgene | PRKG1 | C0234249 | Neuralgia, Stump | 1 | CTD_human |
Tgene | PRKG1 | C0236733 | Amphetamine-Related Disorders | 1 | CTD_human |
Tgene | PRKG1 | C0236804 | Amphetamine Addiction | 1 | CTD_human |
Tgene | PRKG1 | C0236807 | Amphetamine Abuse | 1 | CTD_human |
Tgene | PRKG1 | C0282313 | Condition, Preneoplastic | 1 | CTD_human |
Tgene | PRKG1 | C0423711 | Neuralgia, Perineal | 1 | CTD_human |
Tgene | PRKG1 | C0423712 | Neuralgia, Iliohypogastric Nerve | 1 | CTD_human |
Tgene | PRKG1 | C0751371 | Neuralgia, Ilioinguinal | 1 | CTD_human |
Tgene | PRKG1 | C0751372 | Nerve Pain | 1 | CTD_human |
Tgene | PRKG1 | C0751373 | Paroxysmal Nerve Pain | 1 | CTD_human |